Matinas BioPharma Holdings Inc - Asset Resilience Ratio
Matinas BioPharma Holdings Inc (MTNB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Matinas BioPharma Holdings Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Matinas BioPharma Holdings Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Matinas BioPharma Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MTNB market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Matinas BioPharma Holdings Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Matinas BioPharma Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Matinas BioPharma Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Matinas BioPharma Holdings Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Matinas BioPharma Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $12.64 Million | -- |
| 2023-12-31 | 35.73% | $8.97 Million | $25.10 Million | +7.92pp |
| 2022-12-31 | 27.81% | $21.93 Million | $78.87 Million | -18.81pp |
| 2021-12-31 | 46.62% | $28.59 Million | $61.33 Million | -18.54pp |
| 2020-12-31 | 65.17% | $46.25 Million | $70.97 Million | +51.24pp |
| 2019-12-31 | 13.93% | $5.61 Million | $40.24 Million | +12.85pp |
| 2017-12-31 | 1.07% | $155.00K | $14.42 Million | -0.51pp |
| 2016-12-31 | 1.59% | $156.00K | $9.82 Million | +0.40pp |
| 2015-12-31 | 1.19% | $100.00K | $8.41 Million | -1.79pp |
| 2014-12-31 | 2.97% | $100.00K | $3.36 Million | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more